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Abstract
The TAM receptors Tyro3, Axl, and Mertk are receptor tyrosine kinases that dampen host innate 
immune responses following engagement with their ligands, Gas6 and Protein S, which recognize 
phosphatidylserine on apoptotic cells. In a form of apoptotic mimicry, many enveloped viruses 
display phosphatidylserine on the outer leaflet of their membranes, enabling TAM receptor 
activation and down-regulation of antiviral responses. Accordingly, we hypothesized that a 
deficiency of TAM receptors would enhance antiviral responses and protect against viral infection. 
Unexpectedly, mice lacking Mertk and/or Axl but not Tyro3 exhibited greater vulnerability to 
infection with neuroinvasive West Nile and La Crosse viruses. This phenotype was associated with 
increased blood-brain barrier permeability, which enhanced virus entry into and infection of the 
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brain. Activation of Mertk synergized with IFN-β to tighten cell junctions and prevent virus transit 
across brain microvascular endothelial cells. Because TAM receptors restrict pathogenesis of 
neuroinvasive viruses, these findings have implications for TAM antagonists that are currently in 
clinical development.
INTRODUCTION
The TAM receptors Tyro3, Axl, and Mertk have pleiotropic functions in cancer metastasis, 
angiogenesis, thrombus stabilization, and innate immune regulation
1,2. Axl and/or Mertk are 
expressed on cells involved in immune control and trafficking, including macrophages, 
dendritic cells (DCs), platelets, and endothelial cells
1
. In comparison, Tyro3 expression is 
prominent on central nervous system (CNS) neurons
3
. TAM receptors signal upon 
recognition of their phosphatidylserine-bound ligands, Gas6 and Protein S
4
. The 
consequences of TAM signaling depend on cell type. For example, TAM receptors are 
important for NK cell development
5
, and their inhibition may license NK cells to reject 
metastatic tumors
6
. Axl and Mertk signaling in endothelial cells modulates angiogenesis
7-9, 
whereas their signaling in platelets promotes thrombus stabilization
10
. In DCs, activation of 
Axl down-regulates production and signaling of pro-inflammatory cytokines by interacting 
physically with the R1 subunit of the type I interferon (IFN) receptor (IFNAR1) to promote 
expression of the negative regulators SOCS1 and SOCS3
11
. The TAM receptors also have 
essential roles in clearance of apoptotic cells by macrophages, retinal pigment epithelial 
cells, and other professional phagocytes
12-14. The TAM ligands Gas6 and Protein S 
physically bridge a TAM receptor expressed on the surface of a phagocyte to 
phosphatidylserine expressed on the surface of the apoptotic cell.
TAM receptors are therapeutic targets in cancer because of their effects on tumor 
angiogenesis, NK cell licensing, tumor cell survival, metastasis, and immune suppression in 
tumor-associated macrophages
6-9. Several antagonists and blocking antibodies are under 
evaluation in clinical trials
15,16. TAM receptor agonists also may prove useful in the 
treatment of autoimmunity because of their ability to down-regulate cytokine production
17
. 
Less is known about the net effect of TAM receptor blockade during viral infection. In a 
form of apoptotic mimicry, many enveloped viruses incorporate phosphatidylserine into their 
virion membranes
18,19 and bind Gas6 and Protein S to facilitate recognition by TAM 
receptors and activation of signals that dampen antiviral responses
19
. Studies with influenza 
and respiratory syncytial viruses suggest that Axl blockade by antibodies protects against 
infection and disease pathogenesis
20
. However, an antiviral phenotype after TAM inhibition 




We hypothesized that deletion of TAM receptors might restrict WNV infection and protect 
against pathogenesis for two reasons: (1) cell culture studies indicated that TAM receptors 
can augment flavivirus entry
18
 and create a more permissive innate immune environment for 
replication
19
; and (2) WNV causes significant morbidity in humans after it crosses the 
blood-brain barrier (BBB) and replicates within neurons. Type I IFN signaling strengthens 
the BBB during viral infection by tightening junctions between brain microvascular 
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. Since TAM receptors can negatively regulate type I IFN 
signaling
11,19, deletion of TAM receptors could enhance both IFN signaling and BBB 
integrity. Unexpectedly, we observed that Axl–/–, Mertk–/–, Axl–/–Mertk–/– but not Tyro3–/– 
mice were more vulnerable to WNV infection. This phenotype was associated with 
markedly impaired BBB integrity during infection. Our results establish a preferential role 
for Mertk in protecting against neuroinvasive viruses, which occurs at least in part through 
its ability to sustain the BBB during infection.
RESULTS
Axl and Mertk but not Tyro3 are required for control of WNV infection in vivo
To evaluate the role of TAM receptors in WNV infection, we infected WT, Tyro3–/–, Axl–/–, 
Mertk–/–, and Axl–/–Mertk–/– C57BL/6 mice with WNV (New York 2000 strain) by 
subcutaneous inoculation (Fig 1a). Unexpectedly, Axl–/–, Mertk–/–, and Axl–/–Mertk–/–, but 
not Tyro3–/– mice were more vulnerable to WNV infection than WT mice, with ~80% 
mortality in Axl–/– or Mertk–/– mice (P < 0.0005) and ~95% mortality in Axl–/–Mertk–/– 
mice (P < 0.0005).
We found that an absence of TAM receptors had a relatively minor effect on viral burden in 
peripheral organs, with increased viremia and viral load observed only at 2 days post-
infection (dpi) in serum (26-fold, P < 0.05) and 4 dpi in the spleen (33-fold, P < 0.05), 
respectively, in the Axl–/–Mertk–/– mice (Fig 1b–c). No significant differences in viral 
burden were observed in serum, spleen, or kidney in Axl–/– or Mertk–/– mice compared to 
WT mice (Fig 1b–d).
Higher levels of WNV infection were apparent in the CNS of Axl–/–, Mertk–/–, and 
Axl–/–Mertk–/– mice compared to WT controls. At 4 dpi, WNV was detected in CNS tissues 
of TAM receptor deficient mice: 2 of 9 Axl–/–, 2 of 10 Mertk–/–, and 3 of 10 Axl–/– Mertk–/– 
mice had brain homogenates that were positive for infectious WNV compared to 0 of 10 WT 
mice (Fig 1e). Analogously, at 6 dpi, 5 of 9 Axl–/–, 4 of 8 Mertk–/–, and 4 of 9 
Axl–/–Mertk–/– mice had detectable WNV in the spinal cord compared to 0 of 10 WT mice 
(Fig 1f). Viral titers also were increased at 8 dpi in the brain (29 to 72-fold increase, P < 
0.05) and spinal cord (7 to 135-fold increase, P < 0.05) of Axl–/–, Mertk–/–, and Axl–/– 
Mertk–/– mice.
Higher levels of CNS infection in the TAM receptor KO animals could suggest that Axl or 
Mertk restrict viral replication preferentially in target cells of the CNS. To test this 
hypothesis, we inoculated WNV intracranially in Axl–/–, Mertk–/–, or Tyro3–/– mice. To 
ensure detection of small differences that might be missed by whole brain analysis, viral 
burden in the cerebral cortex, subcortex, brain stem, and cerebellum was measured at 3, 5, 
and 6 dpi after infection. However, no difference in viral burden in the CNS of Axl–/–, 
Mertk–/–, or Tyro3–/– mice was observed following intracranial inoculation (Fig 1g–i, P > 
0.9). These data suggest that TAM receptors do not restrict WNV replication directly in the 
CNS.
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Effects of TAM receptors on antiviral adaptive immune responses
To assess whether part of the CNS virological phenotype could be attributed to defects in 
adaptive immunity, we measured anti-WNV IgM and IgG levels at 4 and 8 dpi in WT and 
Axl–/–Mertk–/– mice (Supplementary Fig 1a–c). Axl–/–Mertk–/– mice had slightly greater 
anti-WNV IgG titers (2.5-fold, P < 0.005) and slightly lower neutralizing titers at 8 dpi (0.4-
fold, P < 0.005). These small differences were unlikely to explain the prominent lethality 
phenotype observed in Axl–/–Mertk–/– mice after WNV infection.
Axl has been proposed to modulate CD8+ T cell responses by DC efferocytosis and antigen 
cross-presentation
21
. To test whether Axl and Mertk affected T cell responses during WNV 
infection, we measured the levels and antigen specificity of CD8+ T cells from the spleen of 
WNV-infected WT, Axl–/–, Mertk–/– and Axl–/–Mertk–/– mice (Supplementary Fig 1d–n). 
Although we detected similar numbers and percentages of CD4+ and CD8+ T cells in the 
spleens of WT, Axl–/–, Mertk–/– and Axl–/–Mertk–/– mice at 8 dpi, we observed fewer WNV 
tetramer-positive CD8+ T cells in Axl–/– mice (Supplementary Fig 1d–f). After ex vivo 
peptide restimulation of splenocytes, we observed a lower percentage and number of WNV-
specific CD8+ T cells that expressed IFN-γ in Axl–/– but not in Mertk–/– CD8+ T cells 
(Supplementary Fig 1k–l, P < 0.05). There also were fewer WNV-specific CD8+ T cells 
that expressed IFN-γ or TNF-α from Axl–/–Mertk–/– mice (Supplementary Fig 1m–n, P < 
0.05). These data suggest that Axl is required for optimal priming of a CD8+ T cell response 
during WNV infection.
We next assessed leukocyte responses within the brain at 8 dpi. We observed greater 
numbers of leukocytes and antigen-specific CD8+ T cells in the brains of Mertk–/– and 
Axl–/–Mertk–/– mice than WT controls (Supplementary Fig 2a–g, P < 0.05) but no 
statistically significant difference in the number of CD11b+CD45hi macrophages or 
CD11b+CD45lo microglia (Supplementary Fig 2h–i). Greater numbers of infiltrating 
immune cells likely result from the higher viral burden in the CNS, enhanced BBB 
permeability, or both.
BBB integrity during WNV infection requires Axl and Mertk but not Tyro3
Because we observed early accumulation of WNV in the brains of Axl–/–, Mertk–/–, and 
Axl–/–Mertk–/– mice, we assessed whether these mice had altered BBB permeability that 
could impact virus entry into the CNS. We injected sodium fluorescein (molecular weight 
(MW): 376) intraperitoneally into naïve and WNV-infected WT, Tyro3–/–, Axl–/–, Mertk–/–, 
and Axl–/–Mertk–/– mice and measured extravasation into the brain 45 minutes later (Fig 
2a). Even in the absence of infection, naïve Axl–/–Mertk–/– mice had slightly greater BBB 
permeability; in comparison, no statistically significant differences were observed in naïve 
Tyro3–/–, Axl–/–, or Mertk–/– mice, although there was a trend toward enhanced BBB 
permeability in uninfected Mertk–/– mice (Fig 2a, left panel). WNV infection resulted in 
increased sodium fluorescein extravasation into the CNS at 4 dpi (Fig 2a, right panel), as 
reported previously
22
. BBB permeability was greater in WNV-infected Axl–/–, Mertk–/–, and 
Axl–/–Mertk–/–, but not Tyro3–/– mice compared to WT mice at this time point, with 
Mertk–/– and Axl–/–Mertk–/– mice exhibiting the most pronounced phenotypes (Fig 2a, right 
panel). These results suggest that Axl and Mertk are required to maintain BBB integrity 
Miner et al. Page 4













during infection and prevent early virus invasion into the CNS, with Mertk having the most 
prominent effect.
As an independent measure of BBB permeability, we used confocal microscopy to assess 
leakage of endogenous IgG (MW: 150,000) into the brain parenchyma following WNV 
infection. Although minimal IgG was detected in the brains of uninfected mice 
corresponding to all genotypes (data not shown), IgG accumulation became apparent at 4 
dpi, with Axl–/–Mertk–/– mice exhibiting greater leakage than WT mice (Fig 2b). Thus, in 
the context of WNV infection, the BBB of Axl–/–Mertk–/– mice was more permeable to 
small molecules and larger proteins.
TAM antagonist disrupts BBB integrity and accelerates WNV infection in the brain
To corroborate the phenotypes observed with TAM receptor KO mice, we treated WT mice 
with a 40 mg/kg dose of BMS-777607, a small molecule inhibitor of c-Met, Ron, Flt-3, and 
TAM receptor signaling
23
, by oral gavage beginning one day prior to WNV infection and 
continuing until 4 dpi. BMS-777607 treatment resulted in enhanced lethality of WT mice 
after WNV infection (Supplementary Fig 3a, P < 0.05) with virus present in the brain at 4 
dpi in 3 of 6 drug-treated mice compared to 0 of 6 control mice (Supplementary Fig 3b). 
BMS-777607 increased BBB permeability in WT but not Axl–/– Mertk–/– mice at 4 dpi 
(Supplementary Fig 3c P < 0.05), nor in drug-treated uninfected animals (Supplementary 
Fig 3d).
TAM receptor KO mice are vulnerable to La Crosse virus infection
We hypothesized that Mertk–/– mice also might be vulnerable to other viruses that enter the 
brain through a hematogenous route. La Crosse virus (LACV) is a neurotropic 
orthobunyavirus that causes meningoencephalitis, predominantly in children
24
. We observed 
enhanced mortality in Axl–/– or Mertk–/– mice infected with LACV compared to WT mice 
(Fig 3a, 50% versus 9%, P < 0.05). Mertk–/– mice had increased BBB permeability at 4 dpi 
whereas LACV-infected Axl–/– mice did not (Fig 3b). We also found higher levels of viral 
RNA in the brains of Mertk–/– but not Axl–/– mice at 8 dpi (Fig 3c) after LACV infection.
Cytokine and chemokine levels in serum of WNV-infected mice
Elevated levels of some pro-inflammatory cytokines (e.g., TNF-α) open the BBB
25
, whereas 
others (e.g., type I IFN) close the barrier
22
. Because TAM receptors negatively regulate 
cytokine production, we measured their levels in the serum of naïve and WNV-infected mice 
(Supplementary Fig 4). In naïve mice, Axl–/–, Mertk–/–, and Axl–/–Mertk–/– mice had 
higher levels of IL12-p40 although other pro-inflammatory cytokines were similar compared 
to WT animals. At 4 dpi, levels of TNF-α, IL-1β, IL-6, IL-12(p40), RANTES, and KC were 
slightly (~2-to-3 fold, P < 0.05) higher in the serum of Axl–/–, Mertk–/–, and Axl–/–Mertk–/– 
mice (Supplementary Fig 4a–g). Type I IFN levels in serum also were slightly higher at 4 
dpi in Axl–/– and Axl–/–Mertk–/– mice (1.3- to 1.5-fold P < 0.05) but not in Mertk–/– mice (P 
> 0.9) (Supplementary Fig 4h).
We also assessed cytokine levels in the brains of Axl–/–, Mertk–/–, and Axl–/–Mertk–/– mice 
that were inoculated via intracranial injection with WNV (Supplementary Fig 4i) in order 
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to measure cytokine expression levels in the context of equivalent WNV burden in WT and 
TAM receptor-deficient mice (see Fig 1g–i). We found no difference in expression of TNF-
α, IL-1β, IL-6, TGF-β1 and TGF-β3 mRNA among any of the genotypes. Consistent with 
this finding, antibody blockade of TNF-α in vivo did not change the BBB permeability 
defect in Axl–/–Mertk–/– mice during WNV infection (data not shown). The net effect of 
differences in levels of pro-inflammatory cytokines on BBB permeability in TAM receptor-
deficient mice remains unclear.
Axl and Mertk signaling improves BBB integrity in vitro
TAM receptors are present on the surface of mouse BMECs in vivo and in vitro, with higher 
expression of Mertk compared to Axl
26,27 (Supplementary Fig 5a–c). To explore whether 
TAM receptor signaling modulates endothelial barrier integrity and WNV transit, we used an 
in vitro model of the BBB
22
. Primary mouse BMECs are cultured in the upper chamber of a 
transwell, with primary astrocytes in the lower chamber. Transendothelial electrical 
resistance (TEER) across the BMEC monolayer measures barrier integrity, with higher 
resistance indicating a tighter barrier. TEER was lower across Axl–/–Mertk–/– BMECs (Fig 
4a, P < 0.05) at baseline. In response to WNV infection, and as expected, WT and 
Axl–/–Mertk–/– BMEC barriers exhibited increased TEER compared with mock-infected 
barriers, but Axl–/–Mertk–/– BMEC barriers failed to tighten as much as WT BMECs (Fig 
4a–b, 0.85-fold, P < 0.0001). We observed no difference in WT and Axl–/–Mertk–/– BMEC 
viability (data not shown).
We next evaluated whether changes in TEER in Axl–/–Mertk–/– BMECs impacted transit of 
WNV across the endothelial barrier. We added WNV to the upper chamber and after 6 h 
measured virus that had crossed the BMEC barrier into the lower chamber; this time point 
precedes de novo spread of WNV infection
28
. Consistent with lower TEER, Axl–/–Mertk–/– 
BMECs had higher amounts (9-fold, P < 0.0001) of WNV crossing into the lower chamber 
compared to WT cells (Fig 4c). Higher levels of WNV in the lower chamber could result 
from decreased binding of WNV to BMECs in the absence of Axl and Mertk, since these 
receptors are engaged by WNV at the plasma membrane
18
. However, we found slightly 
higher amounts of WNV associated with BMECs lacking Axl and Mertk expression at 6 h 
after infection (Fig 4d). Thus, Axl and Mertk are not required for binding of WNV to 
BMECs, and TAM receptor signaling sustains the integrity of the endothelial barrier, which 
restricts WNV transit.
The decrease in TEER in response to WNV infection in Axl–/–Mertk–/– BMECs might be 
due to an altered production or response to cytokines (e.g., TNF-α), which independently 
affect the barrier. Indeed, we detected slightly increased levels (1.4- to 2.6-fold P < 0.05) of 
TNF-α, IL-1β, and IFN-γ during WNV infection of BMECs (Fig 4e–f, and data not shown). 
Other cytokine and chemokine levels (e.g., IL-2, IL-3, IL-6, IL-13, KC, MIP1α, RANTES) 
were similar in WT and BMECs (data not shown). Since TNF-α and IL-1β can disrupt BBB 
integrity
22
, we tested whether blockade of these cytokines in vitro during WNV infection 
might differentially alter barrier integrity. Treatment of BMECs with blocking antibodies 
against IL-1β and TNF-α prior to infection minimally increased TEER (1.1 to 1.2-fold, P < 
0.05) in both WT and Axl–/–Mertk–/– BMECs, and this effect was evident only at late time 
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points (Fig 4g). As studies have suggested that TAM receptors can modulate the 
responsiveness of endothelial cells to TNF-α
22
, we treated WT and Axl–/–Mertk–/– BMECs 
with soluble TNF-α; however no difference in TEER was observed (P > 0.9, Fig 4h).
As Axl associates physically with IFNAR1 and modulates type I IFN signaling in DCs
11
, we 
hypothesized that TAM receptors might affect IFNAR signaling in BMECs, which could 
affect BBB tightening after WNV infection. To test this idea, we treated WT or 
Axl–/–Mertk–/– BMECs with IFN-β (IFNAR-dependent) or IFN-λ (IFNAR-independent) and 
measured TEER over 6 hours. Whereas a deficiency of Axl and Mertk did not affect the 
ability of IFN-λ to increase TEER
22,29, Axl–/–Mertk–/– BMECs were less responsive to IFN-
β treatment in terms of TEER changes (Fig 4i), although IFNAR expression was similar in 
WT and Axl–/–Mertk–/– BMECs (Supplementary Fig 5d). These results suggest that Axl 
and Mertk expression in BMECs is required for the full effect on barrier integrity of IFN-β. 
Colocalization of the tight junction (TJ) proteins claudin-5 and ZO-1 is enhanced by type I 
IFN during WNV infection
22
. We observed diminished claudin-5 expression at the cell 
membrane in addition to discontinuities in TJs in Axl–/–Mertk–/– BMECs (Fig 4j). 
Treatment of WT and Axl–/–Mertk–/– BMECs with IFN-β or IFN-λ enhanced ZO-1 and 
claudin-5 colocalization in WT and Axl–/–Mertk–/– BMECs, although discontinuities in TJs 
were still observed in Axl–/–Mertk–/– BMECs. In contrast, treatment with TNF-α disrupted 
TJ in both WT and Axl–/–Mertk–/– BMECs. Diminished TJ integrity, increased virus transit, 
and altered IFN-β responsiveness in Axl–/–Mertk–/– BMECs may explain how endothelial 
cell expression of TAM receptors can enhance BBB integrity during viral infection.
We next tested the effects of Gas6
4
, which binds to and activates both Axl and Mertk, either 
alone or in combination with IFN-β, on TEER in WT BMECs. We observed dose-dependent 
tightening of BMEC monolayers in response to Gas6 (Fig 5a). The combination of Gas6 and 
IFN-β rapidly tightened the barrier, with markedly increased TEER values observed within 
15 min of treatment. Similar increases in TEER values were observed in a human BMEC 
line and with physiologic concentrations of Protein S, which functions as a ligand for Mertk 
and Tyro3 but not Axl
4
 (Supplementary Fig 6a–b). Consistent with its dominant role in 
maintaining BBB integrity in vivo (see Fig 2a and 3b), signaling through Mertk was 
required for the increase in TEER in response to Gas6 (Fig 5d). Whereas Tyro3–/– and 
Axl–/– BMECs responded to Gas6 similarly compared to WT cells (Fig 5b–c), Axl–/– 
BMECs exhibited decreased baseline TEER (Fig 5c). A combined genetic deficiency of 
Axl–/– and Mertk–/– did not increase the barrier defect beyond that observed in Mertk–/– 
BMECs in response to Gas6 and IFN-β (Fig 5d–e).
To investigate further the interaction between TAM receptor and type I IFN signaling, we 
treated Ifnar–/– BMECs with Gas6. Type I IFN signaling was not required for Gas-6-
dependent effects on TEER at 30 and 60 minutes after treatment, although an absence of 
IFNAR diminished the amplitude of the effect at all time points (Supplementary Fig 7a). 
We confirmed these findings with MAR1-5A3
30
, an IFNAR-blocking antibody, which was 
incubated with WT BMECs immediately prior to Gas6 addition (Supplementary Fig 7b). 
Thus, TAM receptor ligands activate Mertk to tighten the junctions of BMEC monolayers in 
a manner that cooperates with but does not require IFNAR signaling, and the effect of Mertk 
on endothelial barrier integrity is amplified when type I IFN signaling occurs concurrently.
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We examined how Gas6-dependent TAM receptor signaling affected the activity of Rac1, a 
Rho family GTPase that regulates cytoskeletal dynamics, TJ integrity, and paracellular 
permeability
31
. IFN-β enhances BMEC barrier formation in part by activating Rac1
22
, and 
Mertk signaling promotes Rac1 activation in macrophages in the context of phagocytosis of 
apoptotic debris
32
. We measured GTP-bound, activated Rac1 after treatment with IFN-β, 
Gas6, or IFN-β and Gas6. Notably, Gas6 treatment was sufficient to enhance Rac1 activation 
in BMECs, similar to the effect of IFN-β alone (Fig 5f, 2-fold, P < 0.005). The combination 
of Gas6 and IFN- β led to a further increase in Rac1 activation. Finally, blockade of Rac1 
activation prevented Mertk- or IFN-β-dependent tightening of BMEC barriers (Fig 5g). 
Thus, cytoskeletal reorganization resulting from Gas6-induced activation of Rac1 is likely 
required to sustain TJ integrity and the endothelial barrier.
We evaluated Axl and Mertk expression in cells of the neurovascular unit by confocal 
microscopy (Supplementary Fig 8a–b). In addition to expression on endothelial cells 
(Supplementary Fig 5a–c), we observed co-staining of TAM receptors in S100β+ astrocytes 
and CD11b+ myeloid cells. To evaluate whether TAM receptor expression on astrocytes 
contributed to endothelial barrier integrity, using the in vitro BBB model, we tested whether 
the TEER response to Gas6 stimulation was different with WT versus Axl–/–Mertk–/– 
astrocytes. However, deletion of Axl and Mertk in astrocytes had no effect on TEER (Fig 
6a).
The effect of Mertk expression on BBB permeability occurred both in vitro and in vivo, 
without appreciable effects on viral replication in peripheral organs or on CD8+ T cell 
responses. To confirm that the dominant effect on BBB permeability of Mertk occurred at 
the level of the neurovascular unit and not in peripheral immune cells, we generated Mertk 
bone marrow chimeric mice. To prevent adventitious effects of radiation on the BBB, the 
heads of mice were shielded with lead (Fig 6b). Bone marrow chimeras with Mertk-
deficient radio-resistant non-hematopoietic cells (SJL→Mertk–/–) exhibited the same BBB 
permeability defect on day 4 after WNV infection as Mertk–/– mice whereas the reciprocal 
chimeras (Mertk–/–→SJL) with Mertk-sufficient non-hematopoietic cells did not (Fig 6c). A 
trend towards a parallel effect on viral burden was observed with 7 of 8 SJL→Mertk–/– mice 
having detectable WNV RNA in the brain at 4 dpi compared to 3 of 8 Mertk–/–→SJL mice 
(Fig 6d, P = 0.06). These results are consistent with a model in which Mertk expression on 
radio-resistant cells within the CNS is required for maintenance of BBB integrity.
DISCUSSION
Many enveloped viruses bind to and activate TAM receptors to disable innate immune 
responses and enhance infection
19
. Because we previously observed slightly lower levels of 
WNV replication in Axl–/–Mertk–/– DCs
19
, we hypothesized that TAM receptor-deficient 
mice would be protected against lethal WNV infection. However, we show here that a 
genetic deficiency of Axl and Mertk resulted in the early appearance of WNV into the CNS, 
which resulted in enhanced viral load and mortality. The increased mortality was associated 
with increased BBB permeability and revealed a dominant role for Mertk in maintaining the 
integrity of this key barrier during viral infection. Using an in vitro BBB model, we found 
that Mertk promoted endothelial barrier integrity by maintaining the co-localization of TJ 
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proteins. The barrier-tightening effect of Mertk signaling was cooperative with the response 
to IFN-β.
Our discovery that Axl–/– and Mertk–/– mice were more vulnerable to neuroinvasive WNV 
and LACV infections suggests that although enveloped viruses can usurp TAM receptors, 
these proteins nonetheless can restrict the pathogenesis of some viruses that gain entry into 
the CNS. When WNV was introduced directly in the CNS by intracranial injection in TAM 
receptor-deficient animals, no increase in viral replication in different brain regions was 
observed. Thus, blockade or ablation of TAM receptors may have varying effects on viral 
pathogenesis depending on the balance between virus binding to TAM receptors via Protein 
S and/or Gas6 and the resulting effects on the intracellular antiviral environment and/or 
vascular endothelial barrier integrity. Our data also demonstrate a separate role of Axl in 
modulating T cell immunity, which could impact viral clearance in different tissues 
including the CNS.
Although we did not assay the level of infection in TAM-deficient DCs in vivo, peripheral 
viral burden was similar in WT, Axl–/–, and Mertk–/– animals, suggesting that the earlier and 
greater viral burden in the CNS reflects accelerated virus entry due to impaired BBB 
integrity and that TAM receptor engagement by WNV is not required for infection in vivo. 
However, WNV infection was slightly greater in blood and the spleen of Axl–/–Mertk–/– 
animals, the mechanism for which requires further study. Bone marrow chimera studies 
revealed that the BBB permeability phenotype tracked with a loss of Mertk expression on 
radio-resistant and not radio-sensitive hematopoietic cells. Mertk+ radio-resistant cells in the 
CNS also include microglia
33,34, which can express Axl upon activation; as such, we do not 
exclude the possibility that the enhanced lethality in WNV-infected Axl–/– mice might 
reflect a role for this TAM receptor in microglia.
IFNAR-dependent signaling was required for optimal endothelial cell barrier integrity after 
treatment with the TAM ligand, Gas6. Studies in myeloid cells have shown that Axl 
associates with and signals through the IFNAR1 subunit
11
, and it is plausible that Mertk 
could function analogously in endothelial cells. Although biochemical corroboration is 
required, Mertk may modulate the barrier tightening effects of IFN-β in endothelial cells 
because of a specific interaction with IFNAR1
11
.
The defects in the stabilization of endothelial TJs in Axl–/–Mertk–/– BMECs are consistent 
with TAM receptor-dependent regulation of cytoskeletal reorganization in other cell types, 
which occur through Rac1
32,35. We observed Rac1 activation in response to Gas6 in 
endothelial cells, which was amplified with concurrent IFN-β treatment. Our experiments 
are consistent with a model in which TAM receptor (preferentially Mertk) and IFNAR 
signaling together activate Rac1, which leads to tightening of BMEC junctions and 
restriction of virus transit into the CNS (Fig 6e).
Axl–/– mice had impaired CD8+ T cell responses to WNV infection, which could impact 
mortality by affecting CNS viral clearance
36,37. We did not observe CD8+ T cell defects in 
peripheral or CNS tissues of Mertk–/– mice, suggesting distinct functions of Axl and Mertk 
in modulating adaptive immunity during virus infections. A diminished T cell response in 
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Axl–/– mice is consistent with a prior study of HSV infection 
21
. However, the attenuated 
CD8+ T cell response does not explain the early appearance of WNV in the brain at day 4 in 




Prior reports have suggested possible functions of TAM receptors in endothelial cells. Mice 
lacking all three TAM receptors (Axl–/–Mertk–/–Tyro3–/– TKO) reportedly have a disrupted 
BBB, although this was attributed in part to autoimmune disease
39
. Exogenous 
administration of Protein S enhanced BBB integrity after ischemic stroke, although this 
phenotype required Tyro3 and not Axl or Mertk
26
. Thus, individual TAM receptors may 
have unique roles in maintaining BBB integrity under different inflammatory conditions. 
Mertk may have a dominant function in maintaining the BBB after viral infection, whereas 
Tyro3, which also is expressed on neurons, may be more important in the context of cerebral 
ischemia. Protein S, which is a ligand for both Tyro3 and Mertk, but not Gas6, is likely to be 




Our discovery that TAM signaling regulates BBB integrity in the context of viral infections 
has clinical implications, since TAM receptor antagonists are being developed as cancer 
therapies
41
. Mertk blockade could increase the risk of neuroinvasion and pathogenesis of 
certain viruses, including WNV and LACV. Indeed, in studies with a broad-spectrum 
inhibitor of TAM signaling
42
, we observed increased lethality after WNV infection and 
increased BBB permeability. Further experiments are warranted to define the net effects of 




The WNV strain (3000.0259) was isolated in New York in 2000 and passaged once in C6/36 
Aedes albopictus cells. Mice were inoculated subcutaneously in the footpad with 102 plaque 
forming units (pfu) of WNV diluted in Hanks balanced salt solution. Viral titers in tissues 
were analyzed by plaque assay using Vero cells, as described previously. The LACV strain 
(original strain) was provided by Andrew Pekosz (Johns Hopkins University, Baltimore, 
Maryland, USA) and passaged twice in Vero cells to produce a virus stock.
Mice
C57BL/6J wild-type (WT) mice were commercially obtained from Jackson Laboratories. 
Axl–/–, Mertk–/–, Axl–/–Mertk–/–, and Tyro3–/– mice have been published
43
 and were 
backcrossed for ten generations. All mice were housed in a pathogen-free mouse facility at 
the Washington University School of Medicine and experiments were performed in 
accordance with federal and University regulations. The protocols were approved by the 
Institutional Animal Care and Use Committee at the Washington University School of 
Medicine (Assurance Number: A3381-01). Mice (8 to 10 week-old, both sexes) were 
inoculated subcutaneously via footpad injection with 102 pfu of WNV or 105 focus-forming 
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units (ffu) of LACV, both diluted in 50 μl of Hanks balanced salt solution (HBSS) 
supplemented with 1% heat-inactivated fetal bovine serum (FBS). For intracranial infection, 
101 pfu of WNV in 20 μl was injected into the right cerebral hemisphere.
Measurement of viral burden
At specified time points after WNV and LACV infection, serum was obtained by 
intracardiac heart puncture, followed by intracardiac perfusion (20 ml of PBS), and organ 
recovery. Organs were weighed, homogenized using a bead-beater apparatus, and WNV was 
titrated by plaque assay on Vero cells
44
. Brains from LACV- and WNV-infected mice were 
harvested at day 8 after infection and the total RNA was extracted using the RNeasy kit 
(Qiagen). For LACV, viral load in the brain was determined by qRT-PCR. Briefly, all 
reactions were assembled in a final volume of 25 μl with 300 ng of RNA, 10 μM forward 
and reverse primers (LACV: Forward 5’-CCTTGCTGCAGTTAGGATCTTCTT-3’, Reverse 
5’- CCACTCTCCAAATTTAGG-GTTAGC-3’; GAPDH: Forward 5’-
AATGGTGAAGGTCGGTGTG-3’, Reverse: 5’-GTG 
GAGTCATACTGGAACATGTAG-3’), 5 μM probe (LACV: 5’-5’-/56-FAM/ 
AGGCCAAGGCTGCTCTCTCGCGTA-/36-TAMSp/-3'; GAPDH: 5’-/56-FAM/
TGCAAATGG/ZEN/CAGCCCTGGTG/3IABkFQ/-3’) and 12.5 μl of TaqMan master mix 
(Applied Biosystems) using the following cycling condition: 48°C for 30 min, 95°C for 10 
min, followed by 45 cycles of 95°C for 15 s and 60°C for 1 min. Quantitation of WNV RNA 
was performed as previously described
45
. The levels of viral RNA were expressed on a log10 
scale as genomes equivalents/g after comparison with a standard curve produced using serial 
ten-fold dilutions of WNV or LACV RNA.
Quantification of type I IFN activity
Levels of type I IFN were determined using an EMCV cytopathic effect bioassay performed 
in L929 cells as described previously
46
. Serum samples were treated with citrate buffer (40 
mM citric acid, 10 mM KCl, 135 mM NaCl [pH 3.0]) for 10 minutes and neutralized with 
medium containing 45 mM HEPES pH 8.0. The amount of type I IFN per ml of serum was 
calculated from a standard curve using IFN-β (PBL Assay Science). The specificity of the 
antiviral activity was confirmed by pre-incubating L929 cells for 2 hours with 25 μg/ml of 




WT and Axl–/–, Mertk–/–, and Axl–/–Mertk–/– mice were infected with WNV, and at 
specified times blood was collected and serum was prepared. The BioPlex Pro Assay was 
performed according to the manufacturer's protocol (BioRad). The cytokine screen included 
IL-1α, IL-1β, IL-2, IL-3 IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17, 
Eotaxin, G-CSF, GM-CSF, IFN-γ, KC, MCP-1 MIP-1α, MIP-1β, RANTES (CCL5), and 
TNF-α.
BBB permeability measurements
Mice were infected with 102 pfu of WNV or diluent (mock) and BBB permeability was 
assessed after 4 days. Sodium fluorescein (100 mg/ml) was administered via an 
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intraperitoneal route in 100 μl. After 45 minutes, blood was collected by cardiac puncture 
into EDTA-coated tubes. Mice were perfused and CNS tissues were harvested, homogenized 
into PBS, clarified by centrifugation, precipitated in 1% trichloroacetic acid, and neutralized 
with borate buffer (Sigma-Aldrich). Fluorescence emission at 485 and 528 nm was 
determined using a microplate reader Synergy™ H1 and Gen5™ software (BioTek 
Instruments, Inc.). Fluorescein concentration was calculated from a standard curve and 
tissue fluorescence values were normalized to the plasma fluorescence values from the same 
mouse.
Endogenous mouse IgG was detected in brain sections using an AlexaFluor-488 anti-mouse 
IgG antibody. Nuclei were stained with Topro-3. Images were acquired with a laser scanning 
confocal microscope (Zeiss LSM 510 META) and analyzed with LSM image browser 
software (Zeiss).
Drug treatment studies
The small molecular receptor inhibitor BMS-777607 (Selleckchem) was dissolved in DMSO 
at a stock concentration of 52 mg/ml. Mice received either 1 mg BMS-777607 dissolved in 
50 μl DMSO or 50 μl DMSO vehicle control by oral gavage beginning one day prior to 
infection and continuing through day 4 after infection.
B cell and antibody responses
The levels of WNV-specific IgM and IgG were determined using an ELISA against purified 
WNV E protein, as described previously
47
. Plaque reduction neutralization assays on 
BHK21-15 cells were performed after mixing serial dilutions of serum with a fixed amount 




WT and TAM receptor-deficient mice were infected in the footpad with 102 pfu of WNV 
and at 8 days after infection, spleens and brains were harvested after extensive cardiac 
perfusion with PBS. Splenocytes were dispersed into single cell suspensions with a cell 
strainer. Brains were digested collagenase and leukocytes were isolated as previously 
described
49
. Intracellular IFN-γ or TNF-α staining was performed after ex vivo 
restimulation with a Db-restricted NS4B immunodominant peptide using 1 μM of peptide 
and 5 μg/ml of brefeldin A (Sigma) as described
50
. Cells were stained with the following 
antibodies and processed by multi-color flow cytometry on an LSR II flow cytometer 
(Becton Dickinson): CD3 (Becton Dickinson, clone 145-2C11), CD4 (Biolegend, clone 
RM4-5), CD8β (Biolegend, clone YT5156.7.7), CD19 (Invitrogen, clone 6D5), CD45 
(Biolegend, clone 30-F11), CD11b (Becton Dickinson, clone M1/70), IFN-γ (Becton 
Dickinson, clone XMG1.2), TNF-α (Biolegend, clone MP6-XT22). Flow cytometry data 
were analyzed using FlowJo software (Treestar).
Transwell cultures and TEER measurements
WT and TAM receptor-deficient BMECs and WT HCMEC/D3 cells were grown until fully 
polarized in transwell cultures
22
. BMECs were grown above astrocyte cultures, whereas 
HCMEC/D3s were grown without astrocytes. TEER was measured via chopstick electrode 
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with an EVOM voltmeter (World Precision Instruments). Resistance values are reported as 
Ω/cm2, with the resistance value for transwell inserts with no cells subtracted as background. 
TEER measurements were collected at 6 h following infection with WNV at MOI 0.01 or 
treatment with murine IFN-λ3 (100 ng/ml), murine or human IFN-β (10 ng/ml) (PBL Assay 
Science); mock wells were treated with culture medium. To block IFN-α/β signaling, BMEC 
cultures were treated with 25 μg/ml of the blocking MAb MAR1-5A3 for one hour prior to 
infection. A non-binding MAb (GIR-208) was used as an isotype control. To measure virus 
transit across the endothelial barrier, WNV was added to the upper chamber of the transwell 
at an MOI of 0.01. After 6 h, virus in the lower chamber was measured by qRT-PCR. 
Recombinant full-length Gas6 was generated in HEK293 EBNA cells as previously 
described
4
. Human Protein S was purchased from Haematologic Technologies 
(HCPS-0090).
Rac1 studies
Rac1 immunoprecipitation experiments were performed with an activated Rac1 agarose bead 
kit (Cell BioLabs, Inc.) according to the manufacturer's instructions. Purified, GTP-bound 
protein and unpurified BMEC protein lysates were separated via gel electrophoresis on 10% 
bis-Tris gels (Life Technologies) and transferred onto iBlot nitrocellulose transfer 
membranes (Life Technologies) according to standard protocols. To test the effects of Rac1 
inhibition on TEER in BMECs, the Rac1 inhibitor Z62954982 (Cayman Chemical) was 
added at a concentration of 1 mM.
TAM receptor expression
Freshly isolated BMECs were stained with anti-Mertk (R&D Systems AF591) or anti-Axl 
(R&D Systems AF854) antibodies followed by a polyclonal secondary antibody. A control 
goat polyclonal antibody and Axl–/–Mertk–/– BMECs were used to assess the specificity of 
staining. Brain sections were stained with antibodies against Mertk (R&D Systems, AF591), 
Axl (R&D Systems, AF854), s100-β (Abcam, ab41548), CD31 (Becton Dickinson, 550274), 
or CD11b (Becton Dickinson, ab8878).
Bone marrow chimeric mice
Six week-old B6.SJL-Ptprc (CD45.1 SJL, Jackson Laboratories) and CD45.2 Mertk–/– mice 
were anesthetized with ketamine and positioned within lead shielding to limit exposure of 
the brain to radiation
51
. Mice were then placed into a pie container within a cesium 
irradiator so that the head was shielded from the radiation source and then irradiated with a 
dose of 8 Gy. Six hours after irradiation, 107 bone marrow-derived leukocytes of a given 
genotype were injected intravenously in 100 μl of PBS. Seven weeks after bone marrow 
transplantation, reconstitution was confirmed by flow cytometry with greater than 95% of B 
cells, 90% of neutrophils, and ~75% of T cells of donor origin.
Power calculation and data generation
To determine mouse group sizes for individual experiments, power analysis was performed 
using the following values: probability of type I error = 0.05, power = 80%, 5-fold 
hypothetical difference in mean, and population variance. This analysis indicated that 
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minimum sample sizes of 8 animals for virological or immunological studies were required 
to detect an approximately 10-fold level of difference. Studies were performed in an 
unblended manner, and randomization was not used. No animals, samples, or data points 
were excluded from any analysis.
Data analysis
All data was analyzed using Prism software (GraphPad4, San Diego, CA). Kaplan-Meier 
survival curves were analyzed by the log rank test. Differences in viral burden, cytokine 
levels, and cell numbers were analyzed by the Mann-Whitney test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mortality and viral burden in WT and TAM receptor-deficient mice after 
subcutaneous or intracranial infection with WNV
Mice were infected with 102 plaque forming units (pfu) of WNV via a subcutaneous route 
(a–f) or 101 pfu via an intracranial route (g–i). a. Survival analysis of WT, Axl–/–, Mertk–/–, 
Tyro3–/– and Axl–/–Mertk–/– mice after subcutaneous WNV infection. Mice were monitored 
for 28 days for morbidity and mortality. The survival curves were constructed using data 
from three to five independent experiments. The survival differences between WT and 
Axl–/–, Mertk–/–, and Axl–/–Mertk–/– mice were statistically significant by the log-rank test 
(****, P < 0.0001). The numbers of animals were n = 49 for WT, n = 29 for Axl–/–, n = 24 
for Mertk–/–, n = 17 for Tyro3–/–, and n = 48 for Axl–/–Mertk–/–. (b–f) Viral burden was 
measured by plaque assay from serum, spleen, kidney, brain, and spinal cord. Symbols 
represent individual mice pooled from several independent experiments; bars indicate the 
mean of 6 to 10 mice per group. Dotted lines represent the limit of sensitivity of the assay. 
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(g–i) Viral replication in the cerebral cortex, cerebellum, and brain stem was measured by 
plaque assay at days 3, 5, and 6 after infection. Bars indicate the mean of 5 or 6 mice per 
group from two independent experiments. Dotted lines represent the limit of sensitivity of 
the assay. *, P < 0.05; **, P < 0.005; ***, P < 0.0005; **** P < 0.0001 by the Mann-
Whitney test.
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Figure 2. BBB permeability in WT and TAM receptor-deficient mice
(a) WT, Axl–/–, Mertk–/–, Tyro3–/– and Axl–/–Mertk–/– mice were infected via a 
subcutaneous route with 102 pfu of WNV or diluent (mock). BBB permeability was assessed 
at 4 days after infection by measuring the accumulation of sodium fluorescein in CNS 
tissues following intraperitoneal administration. Tissue fluorescence was normalized to the 
plasma fluorescence from the same animal. Symbols represent individual animals from two 
independent experiments. ****, P < 0.0001; *, P < 0.05 (ANOVA with Tukey multiple 
comparisons test). (b) WT and Axl–/–Mertk–/– mice were infected via a subcutaneous route 
with 102 pfu of WNV or diluent (mock). Mice were perfused and brain sections were stained 
with anti-mouse IgG to detect endogenous antibody leakage into the CNS parenchyma. IgG 
staining is shown in green, nuclei are shown in blue. Representative images were taken at 
40X magnification. Scale bar equals 100 μm. Levels of IgG staining were quantified from 2 
fields from 4 independent mice per group. *, P < 0.05 (Mann-Whitney test).
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Figure 3. Vulnerability, viral burden, and BBB permeability in WT, Axl–/–, and Mertk–/– mice 
after infection with LACV
8-week-old mice were infected with 105 focus forming units (ffu) of LACV via a 
subcutaneous route. (a) Survival analysis of WT, Axl–/–, and Mertk–/– mice after LACV 
infection. The survival curves were constructed using data from three independent 
experiments and the differences between WT and Mertk–/– or WT and Axl–/– mice were 
statistically significant (P < 0.05) as judged by the log-rank test; n = 23 for WT, n = 18 for 
Mertk–/–, n = 11 for Axl–/– mice. (b) BBB permeability was measured 4 days after infection 
by sodium fluorescein assay as described in legend to Figure 2. *, P < 0.05 (Mann-Whitney 
test). (c) Viral burden in the brain as measured by qRT-PCR and plotted as genome 
equivalents. n = 12 for WT, n = 12 for Mertk–/–, and n = 12 for Axl–/– mice. ***, P < 0.005 
(Mann-Whitney test).
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Figure 4. Analysis of barrier integrity in brain microvascular endothelial cells from 
Axl–/–Mertk–/– mice
BMECs were prepared from WT or Axl–/–Mertk–/– mice and cultured on transwell inserts 
with astrocytes prepared from WT mice. (a) BMECs were infected with WNV at an MOI of 
0.01 and TEER was measured at two-hour intervals. (b) The relative changes in TEER over 
6 h in WT and Axl–/–Mertk–/– BMECs. (c) Virus crossing into the lower chamber of 
transwells with WT and Axl–/–Mertk–/– BMECs measured by qRT-PCR and expressed as 
pfu equivalents/ml. (d) Measurement of WNV associated with WT and Axl–/–Mertk–/– 
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BMECs. Six hours after the addition WNV (MOI of 0.01), BMECs were rinsed six times 
and RNA was isolated and analyzed by qRT-PCR. (e-f) Cytokine levels in mock-infected 
and WNV-infected BMEC media were measured by Luminex assay. (g) WT and 
Axl–/–Mertk–/– BMECs infected with WNV at a MOI of 0.01 were pre-treated with blocking 
antibodies to IL-1β and/or TNF-α and TEER was measured every 2 hours after infection for 
6h. Results represent mean ± SEM of 9 samples from two independent experiments. ****, P 
< 0.0001; ***, P < 0.0005; **, P < 0.005, *, P < 0.05 (2-way ANOVA). (h) and (i) Cells 
were treated for 6 h with 100 ng/ml of TNF-α, 10 IU/ml murine IFN-β, or 100 ng/ml of 
murine IFN-λ3 for 6 h followed by TEER measurements. (j) BMECs were prepared from 
WT and Axl–/–Mertk–/– mice and grown on chamber slides. Cells were co-stained for the TJ 
proteins ZO-1 (green) and claudin-5 (red); nuclei are shown in blue. Images were taken by 
confocal microscopy at 63X magnification. White arrows indicate diminished colocalization 
of ZO-1 and claudin-5. Yellow arrows indicate TJ discontinuities. Scale bar equals 25 μm. 
Right panel indicates the colocalization of claudin-5 and ZO-1. Values on the y-axis 
(correlation coefficient) represent the probability of an individual pixel staining positive for 
both markers if it stains positive for either. Results are representative of two or three 
independent experiments.
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Figure 5. Mertk signaling tightens BMEC barriers and functions synergistically with IFN-β
BMECs were prepared from WT, Axl–/–, Mertk–/–, Tyro3–/–, Axl–/–Mertk–/– and Ifnar1–/– 
mice and cultured on transwell inserts with astrocytes prepared from WT mice. (a) Dose-
dependent tightening of BMEC barrier integrity as measured by TEER in response to 
treatment with Gas6, IFN-β, or Gas6 + IFN-β. (b–e) TEER measurements after treatment of 
(b) Tyro3–/–, (c) Axl–/–, (d) Mertk–/– or (e) Axl–/– Mertk–/– BMEC monolayers with Gas6 
(left panels) or IFN-β with or without Gas6 (right panels). (f) Rac1 activation as judged by 
immunoprecipitation after treatment of WT BMECs with Gas6, IFN-β, or Gas6 plus IFN-β. 
Miner et al. Page 23













The dose of Gas6 was 10 nM and the dose of IFN-β was 10 IU/ml. (g) TEER measurements 
after treatment of WT or Mertk–/– BMECs with Gas6, IFN-β, or Gas6 + IFN-β Gas6. Each 
group also was treated with the Rac1 inhibitor Z62954982 or with vehicle control. Results in 
this Figure are pooled from at least two independent experiments with 4 to 6 technical 
replicates. ****, P < 0.0001; ***, P < 0.0005; **, P < 0.005, *, P < 0.05 (2-way ANOVA).
Miner et al. Page 24













Figure 6. Enhanced BBB permeability occurs independently of Mertk expression on astrocytes 
and radiosensitive cells
(a) Dose-dependent tightening of WT and Axl–/–Mertk–/– BMEC barrier integrity (grown 
over WT or Axl–/–Mertk–/– astrocytes) as measured by TEER in response to treatment with 
Gas6, IFN-β, or Gas6 + IFN-β. (b) (Top) Scheme of head shielding of mice to prevent 
radiation damage to the BBB. (Bottom) Representative flow cytometry plots showing the 
reconstitution efficiency of CD19+ and CD3+ cells in Mertk–/– and SJL mice after bone 
marrow transplantation. (c) Sodium fluorescein measurement of BBB permeability in 
SJL→Mertk–/– and Mertk–/–→SJL as well as control SJL→SJL and Mertk–/–→Mertk–/– 
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bone marrow chimeric mice 4 days after subcutaneous infection with 102 pfu of WNV; **, P 
< 0.005 (unpaired t test). (d) Measurement of WNV RNA in the brain by qRT-PCR on day 4 
after infection; P = 0.06 (Mann-Whitney test). n = 8 for SJL→Mertk–/–, n = 8 for 
Mertk–/–→SJL, n = 5 for SJL→SJL, n = 5 for Mertk–/–→Mertk–/– mice. (e) Model of 
cooperative IFNAR and TAM receptor signaling to activate Rac1, tighten the BBB, and 
prevent virus entry into the CNS. Signaling through Mertk and to a lesser extent Axl (via 
ligands Gas6 and Protein S) and IFNAR (via IFN-α/β) activate Rac1 within minutes, which 
leads to actin remodeling and stabilization of endothelial cell TJs. The question mark 
between TAM receptors and IFNAR indicates the uncertain mechanism by which IFN 
signaling modulates Mertk- and Axl-induced barrier tightening. Although experimental 
validation is required, a physical interaction between TAM receptors and IFNAR, as has 
been observed in DCs
11
, could explain the observed phenotype.
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